tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Gliosis D005911 6 associated lipids
Kidney Tubular Necrosis, Acute D007683 3 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Hallucinations D006212 4 associated lipids
Sleep Wake Disorders D012893 7 associated lipids
Rosacea D012393 13 associated lipids
Pericarditis D010493 6 associated lipids
Hyperpigmentation D017495 11 associated lipids
Autonomic Nervous System Diseases D001342 4 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Tachycardia, Ventricular D017180 9 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Long QT Syndrome D008133 10 associated lipids
Intestinal Pseudo-Obstruction D007418 5 associated lipids
Mycoses D009181 18 associated lipids
Liver Failure D017093 5 associated lipids
Epilepsy, Temporal Lobe D004833 4 associated lipids
Retinoblastoma D012175 12 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Gastroenteritis D005759 4 associated lipids
Hypertrophy, Left Ventricular D017379 12 associated lipids
Inappropriate ADH Syndrome D007177 4 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Lymphoma, T-Cell D016399 11 associated lipids
Cicatrix, Hypertrophic D017439 4 associated lipids
Pityriasis D010915 3 associated lipids
Hand Dermatoses D006229 5 associated lipids
Postoperative Hemorrhage D019106 7 associated lipids
Liver Abscess D008100 6 associated lipids
Carpal Tunnel Syndrome D002349 3 associated lipids
Foot Dermatoses D005533 3 associated lipids
Anus Diseases D001004 3 associated lipids
Endomyocardial Fibrosis D004719 4 associated lipids
Ataxia Telangiectasia D001260 6 associated lipids
Herpesviridae Infections D006566 4 associated lipids
Leukoencephalopathies D056784 3 associated lipids
Pouchitis D019449 3 associated lipids
Granuloma, Giant Cell D006101 7 associated lipids
Epstein-Barr Virus Infections D020031 3 associated lipids
Labyrinthitis D007762 2 associated lipids
Foot Deformities, Acquired D005531 2 associated lipids
Dermatomyositis D003882 2 associated lipids
Dementia, Vascular D015140 7 associated lipids
Mastocytosis D008415 5 associated lipids
Molluscum Contagiosum D008976 2 associated lipids
Paresis D010291 2 associated lipids
Intracranial Hypertension D019586 4 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Chronic Disease D002908 7 associated lipids
Drug-Related Side Effects and Adverse Reactions D064420 3 associated lipids
Purpura, Thrombotic Thrombocytopenic D011697 6 associated lipids
Vitiligo D014820 2 associated lipids
Hemophilia B D002836 3 associated lipids
Myasthenia Gravis D009157 5 associated lipids
Hyperkalemia D006947 3 associated lipids
Intracranial Thrombosis D020767 2 associated lipids
Pemphigus, Benign Familial D016506 3 associated lipids
Skin Diseases, Vesiculobullous D012872 5 associated lipids
Prurigo D011536 4 associated lipids
Hepatitis, Viral, Animal D006524 4 associated lipids
Cryptococcosis D003453 3 associated lipids
Hepatitis B, Chronic D019694 4 associated lipids
Simian Acquired Immunodeficiency Syndrome D016097 4 associated lipids
Castleman Disease D005871 3 associated lipids
Wounds, Stab D014951 3 associated lipids
Keratosis, Actinic D055623 3 associated lipids
Toxocariasis D014120 3 associated lipids
Fistula D005402 8 associated lipids
Confusion D003221 4 associated lipids
Encephalitis, Viral D018792 3 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Optic Nerve Injuries D020221 4 associated lipids
Hyperuricemia D033461 4 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Viremia D014766 4 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Parotitis D010309 4 associated lipids
Tuberous Sclerosis D014402 2 associated lipids
Ocular Motility Disorders D015835 2 associated lipids
Pain, Intractable D010148 4 associated lipids
Sciatic Neuropathy D020426 13 associated lipids
Perceptual Disorders D010468 3 associated lipids
Polyneuropathies D011115 3 associated lipids
Heart Injuries D006335 6 associated lipids
Hearing Loss, Noise-Induced D006317 4 associated lipids
Exanthema D005076 11 associated lipids
Bronchiolitis D001988 6 associated lipids
Reflex Sympathetic Dystrophy D012019 4 associated lipids
Kartagener Syndrome D007619 2 associated lipids
Earache D004433 2 associated lipids
Delayed Graft Function D051799 2 associated lipids
Gingival Hyperplasia D005885 3 associated lipids
Intussusception D007443 1 associated lipids
Neoplasms, Second Primary D016609 4 associated lipids
Paraparesis, Tropical Spastic D015493 1 associated lipids
Crigler-Najjar Syndrome D003414 1 associated lipids
Apraxias D001072 1 associated lipids
Cholangitis, Sclerosing D015209 1 associated lipids
Venous Insufficiency D014689 2 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Ekberg H Calcineurin inhibitor sparing in renal transplantation. 2008 Transplantation pmid:18813097
Ernst A et al. Lung abcess complicating Legionella micdadei pneumonia in an adult liver transplant recipient: case report and review. 1998 Transplantation pmid:9448158
Cavaillé-Coll MW and Elashoff MR Commentary on a comparison of tacrolimus and cyclosporine for immunosuppression after cadaveric renal transplantation. 1998 Transplantation pmid:9448161
Levy G et al. Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. 2004 Transplantation pmid:15201658
O'Grady J C(2) monitoring: out of the blocks but with some way to go! 2004 Transplantation pmid:15201659
Fung JJ Tacrolimus and transplantation: a decade in review. 2004 Transplantation pmid:15201685
Busuttil RW and Lake JR Role of tacrolimus in the evolution of liver transplantation. 2004 Transplantation pmid:15201686
Gjertson DW et al. The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival. 1995 Transplantation pmid:8545861
Plock JA et al. Adipose- and Bone Marrow-Derived Mesenchymal Stem Cells Prolong Graft Survival in Vascularized Composite Allotransplantation. 2015 Transplantation pmid:26102613
Bunnapradist S et al. Graft survival following living-donor renal transplantation: a comparison of tacrolimus and cyclosporine microemulsion with mycophenolate mofetil and steroids. 2003 Transplantation pmid:12865780
Ajiki T et al. Generation of donor hematolymphoid cells after rat-limb composite grafting. 2003 Transplantation pmid:12640301
Tydén G et al. Implementation of a Protocol for ABO-incompatible kidney transplantation--a three-center experience with 60 consecutive transplantations. 2007 Transplantation pmid:17496528
Silva HT et al. Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipients. 2014 Transplantation pmid:24521771
Faguer S et al. Rituximab therapy for acute humoral rejection after kidney transplantation. 2007 Transplantation pmid:17496547
Arns W et al. Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients: A Multicenter, Randomized Trial. 2017 Transplantation pmid:28658202
Taber DJ et al. Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation. 2017 Transplantation pmid:28658199
Misra S et al. Red cell aplasia in children on tacrolimus after liver transplantation. 1998 Transplantation pmid:9500636
Asako H et al. Reduction of leukocyte adherence and emigration by cyclosporine and L683,590 (FK506) in postcapillary venules. 1992 Transplantation pmid:1384191
Hashimoto T et al. Treatment with FK506 prevents rejection of rat colon allografts. 1994 Transplantation pmid:7516586
van Hooff JP et al. A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients. 2003 Transplantation pmid:12829890
Heffron TG et al. Pediatric liver transplantation with daclizumab induction. 2003 Transplantation pmid:12829908
Gonwa T et al. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. 2003 Transplantation pmid:12829910
Andrés A et al. A randomized trial comparing renal function in older kidney transplant patients following delayed versus immediate tacrolimus administration. 2009 Transplantation pmid:19898206
Larsen JL et al. Tacrolimus and sirolimus cause insulin resistance in normal sprague dawley rats. 2006 Transplantation pmid:16926589
Peloso LJ et al. The serum concentration of tacrolimus after ingesting omeprazole: a pilot study. 2014 Transplantation pmid:25221905
Yang Z et al. Long-term liver allograft survival induced by combined treatment with rAAV-hCTLA4Ig gene transfer and low-dose FK506. 2003 Transplantation pmid:12589149
Fisher NC et al. Chronic renal failure following liver transplantation: a retrospective analysis. 1998 Transplantation pmid:9679823
Ericzon BG et al. The effect of FK506 treatment on pancreaticoduodenal allotransplantation in the primate. 1992 Transplantation pmid:1376501
Gallon L et al. Differential Effects of Calcineurin and Mammalian Target of Rapamycin Inhibitors on Alloreactive Th1, Th17, and Regulatory T Cells. 2015 Transplantation pmid:25905982
Alhamad T et al. Targeting High Calcineurin Inhibitor Levels After Acute Rejection With Less Tremor: A New Strategy. 2017 Transplantation pmid:28422926
Gonwa TA et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. 2001 Transplantation pmid:11773892
Fisher RA et al. A prospective randomized trial of mycophenolate mofetil with neoral or tacrolimus after orthotopic liver transplantation. 1998 Transplantation pmid:9884248
Solez K et al. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. 1998 Transplantation pmid:9884269
Robertsen I et al. Use of generic tacrolimus in elderly renal transplant recipients: precaution is needed. 2015 Transplantation pmid:25148382
Reyes J et al. Expressive dysphasia possibly related to FK506 in two liver transplant recipients. 1990 Transplantation pmid:1701571
Ciancio G et al. Use of intravenous FK506 to treat acute rejection in simultaneous pancreas-kidney transplant recipients on maintenance oral FK506. 1997 Transplantation pmid:9075856
Lenaers JI et al. Relevance of posttransplant flow cytometric T- and B-cell crossmatches in tacrolimus-treated renal transplant patients. 2006 Transplantation pmid:17102764
Bronster DJ et al. Tacrolimus-associated mutism after orthotopic liver transplantation. 2000 Transplantation pmid:11014653
Yamamoto S et al. FK778 and FK506 combination therapy to control acute rejection after rat liver allotransplantation. 2004 Transplantation pmid:15591950
Tan HP et al. Living-related donor renal transplantation in HIV+ recipients using alemtuzumab preconditioning and steroid-free tacrolimus monotherapy: a single center preliminary experience. 2004 Transplantation pmid:15591960
Nashan B et al. Clinical validation studies of Neoral C(2) monitoring: a review. 2002 Transplantation pmid:12023607
Serón D et al. Immunophenotype of infiltrating cells in protocol renal allograft biopsies from tacrolimus-versus cyclosporine-treated patients. 2007 Transplantation pmid:17353788
Sarwal MM et al. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. 2001 Transplantation pmid:11468528
Camirand G et al. Combined immunosuppression of mycophenolate mofetil and FK506 for myoblast transplantation in mdx mice. 2001 Transplantation pmid:11468532
Squifflet JP et al. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. 2001 Transplantation pmid:11468536
Theruvath TP et al. Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection. 2001 Transplantation pmid:11468538
Zervos XA et al. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. 1998 Transplantation pmid:9583863
Araki M et al. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs. 2006 Transplantation pmid:16477217
Gallon L et al. ACE gene D/D genotype as a risk factor for chronic nephrotoxicity from calcineurin inhibitors in liver transplant recipients. 2006 Transplantation pmid:16477235
Moreau C et al. Interaction between tacrolimus and omeprazole in a pediatric liver transplant recipient. 2006 Transplantation pmid:16477241
Shaffer D et al. Normal pancreas allograft function following simultaneous pancreas kidney transplantation after rescue therapy with tacrolimus (FK506). 1995 Transplantation pmid:7535958
Bronster DJ et al. Demyelinating sensorimotor polyneuropathy after administration of FK506. 1995 Transplantation pmid:7535959
Jain A et al. Reasons for long-term use of steroid in primary adult liver transplantation under tacrolimus. 2001 Transplantation pmid:11374410
Neumann UP et al. Significance of a T-lymphocytotoxic crossmatch in liver and combined liver-kidney transplantation. 2001 Transplantation pmid:11374419
Chan K et al. Kidney transplantation with minimized maintenance: alemtuzumab induction with tacrolimus monotherapy--an open label, randomized trial. 2011 Transplantation pmid:21836540
Piao SG et al. Combined treatment of tacrolimus and everolimus increases oxidative stress by pharmacological interactions. 2014 Transplantation pmid:24825522
Gujadhur A et al. CMV sinusitis in a HIV-negative renal transplant recipient. 2014 Transplantation pmid:24827770
Ahsan N et al. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years. 2001 Transplantation pmid:11477347
Andries S et al. Posttransplant immune hepatitis in pediatric liver transplant recipients: incidence and maintenance therapy with azathioprine. 2001 Transplantation pmid:11477351
Riegersperger M et al. Effect of conversion from ciclosporin to tacrolimus on endothelial progenitor cells in stable long-term kidney transplant recipients. 2013 Transplantation pmid:23594858
Kovarik JM et al. Pharmacokinetics of sotrastaurin combined with tacrolimus or mycophenolic acid in de novo kidney transplant recipients. 2011 Transplantation pmid:21157403
Herzog D et al. Normal glomerular filtration rate in long-term follow-up of children after orthotopic liver transplantation. 2006 Transplantation pmid:16534467
Josephson MA et al. Treatment of renal allograft polyoma BK virus infection with leflunomide. 2006 Transplantation pmid:16534472
Taler SJ et al. Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine. 1996 Transplantation pmid:8970613
Chakrabarti P et al. Outcome after steroid withdrawal in pediatric renal transplant patients receiving tacrolimus-based immunosuppression. 2000 Transplantation pmid:11003353
Srinivas TR et al. The impact of mycophenolate mofetil on long-term outcomes in kidney transplantation. 2005 Transplantation pmid:16251854
Roelen DL et al. Differential inhibition of primed alloreactive CTLs in vitro by clinically used concentrations of cyclosporine and FK506. 1993 Transplantation pmid:7687397
Buell JF et al. Malignancy after transplantation. 2005 Transplantation pmid:16251858
Panz VR et al. Diabetogenic effect of tacrolimus in South African patients undergoing kidney transplantation1. 2002 Transplantation pmid:11889436
Charney DA et al. Plasma cell-rich acute renal allograft rejection. 1999 Transplantation pmid:10515379
van Maarseveen EM et al. Pretransplantation pharmacokinetic curves of tacrolimus in HIV-infected patients on ritonavir-containing cART: a pilot study. 2013 Transplantation pmid:23250333
Shivaswamy V et al. Metformin improves immunosuppressant induced hyperglycemia and exocrine apoptosis in rats. 2013 Transplantation pmid:23250335
Gouraud A et al. Follow-up of tacrolimus breastfed babies. 2012 Transplantation pmid:22996303
Randhawa PS et al. Clinical significance of renal biopsies showing concurrent acute rejection and tacrolimus-associated tubular vacuolization. 1999 Transplantation pmid:9921801
Hougardy JM et al. Conversion from Prograf to Advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure. 2011 Transplantation pmid:21192316
Yamani MH et al. The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection. 2000 Transplantation pmid:10868634
Blakolmer K et al. Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: long-term follow-up and evaluation of features for histopathological staging. 2000 Transplantation pmid:10868635
Neuhaus P et al. Quadruple tacrolimus-based induction therapy including azathioprine and ALG does not significantly improve outcome after liver transplantation when compared with standard induction with tacrolimus and steroids: results of a prospective, randomized trial. 2000 Transplantation pmid:10868638
Verleden GM et al. Successful conversion from cyclosporine to tacrolimus for gastric motor dysfunction in a lung transplant recipient. 2002 Transplantation pmid:12131703
Johnson C et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. 2000 Transplantation pmid:10755536
Miller J et al. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group. 2000 Transplantation pmid:10755543
Mohamed MA et al. TGF-beta expression in renal transplant biopsies: a comparative study between cyclosporin-A and tacrolimus. 2000 Transplantation pmid:10755567
Anil Kumar MS et al. Comparison of steroid avoidance in tacrolimus/mycophenolate mofetil and tacrolimus/sirolimus combination in kidney transplantation monitored by surveillance biopsy. 2005 Transplantation pmid:16210969
Ellis D et al. Renal transplantation in children managed with lymphocyte depleting agents and low-dose maintenance tacrolimus monotherapy. 2007 Transplantation pmid:17589338
Lorber MI et al. A comparison of in vivo responses to cyclosporine, FK506, and rapamycin following allogeneic immune challenge. 1991 Transplantation pmid:1713364
Deuse T et al. Significant reduction of acute cardiac allograft rejection by selective janus kinase-1/3 inhibition using R507 and R545. 2012 Transplantation pmid:22971540
Abu-Elmagd K et al. The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. 1991 Transplantation pmid:1713365
Shapiro R et al. Tacrolimus in pediatric renal transplantation. 1996 Transplantation pmid:8990356
Przepiorka D et al. Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus. 1996 Transplantation pmid:8990368
Ko S et al. The pharmacokinetic benefits of newly developed liposome-incorporated FK506. 1994 Transplantation pmid:7526494
Dean PG et al. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. 2004 Transplantation pmid:15239621
Holländer GA et al. Disruption of T cell development and repertoire selection by calcineurin inhibition in vivo. 1994 Transplantation pmid:7526495
Dieterle CD et al. Glucose metabolism after pancreas transplantation: cyclosporine versus tacrolimus. 2004 Transplantation pmid:15239622
Chavin KD et al. Anti-CD2 monoclonal antibodies synergize with FK506 but not with cyclosporine or rapamycin to induce tolerance. 1994 Transplantation pmid:7511258
Inomata Y et al. The evolution of immunosuppression with FK506 in pediatric living-related liver transplantation. 1996 Transplantation pmid:8600632
Tricot L et al. Tacrolimus-induced alopecia in female kidney-pancreas transplant recipients. 2005 Transplantation pmid:16371923
Gruessner RW et al. A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. 1996 Transplantation pmid:8600635
MacPhee IA and Holt DW A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype. 2008 Transplantation pmid:18212618
Cezário ES et al. Gingival overgrowth in renal transplant subjects medicated with tacrolimus in the absence of calcium channel blockers. 2008 Transplantation pmid:18212628
Oku M et al. Hepatocyte growth factor sustains T regulatory cells and prolongs the survival of kidney allografts in major histocompatibility complex-inbred CLAWN-miniature swine. 2012 Transplantation pmid:22158517